This pattern of response was consistently observed in each subgroup assessed (Table 1), including patients with a higher frequency of VOCs in the year prior to study entry (5‐10 VOC events; 28.0% vs 4.2%), with the HbSS genotype (31.9% vs 17.0%), and/or using concomitant HU (33.3% vs 17.5%). The SUSTAIN study evaluated the safety of SelG1, a first-in-class humanized anti-P-selectin antibody, and its effect on the frequency of SCPC in SCD patients. These subgroup analyses also indicate that the efficacy observed in the overall study population was likely not driven by a single subgroup or set of subgroups. The efficacy of ADAKVEO ® (crizanlizumab-tmca) was evaluated based on the annual rate of VOCs in patients (16 to 63 years of age) with SCD in a pivotal, phase 2, 52-week, randomized, multicenter, placebo-controlled, double-blind study. SCD (n=121) was assessed over a median follow-up of 1 year. In the double‐blind, placebo‐controlled phase 2 SUSTAIN study, crizanlizumab (humanized, anti‐P‐selectin monoclonal antibody) 5 mg/kg significantly lowered the rate of VOC in patients with SCD by 45% vs placebo. Before enrollment, all patients provided written informed consent. Thus, HU primarily targets RBCs, whereas crizanlizumab is targeting the vasculature. The study will enroll up to 45 patients and follow patients for approximately two years after infusion. The efficacy and safety of crizanlizumab was studied in a 52-week, randomized, multicenter, placebo-controlled, double-blind, Phase II, clinical trial SUSTAIN (NCT01895361). Use the link below to share a full-text version of this article with your friends and colleagues. A phase 3 trial showed modest efficacy during acute VOC and a second phase 3 trial is currently ongoing. We thank Andrew Jones, from Mudskipper Business Limited, for medical editorial assistance. o SUSTAIN trial data was used to determine the treatment effect of crizanlizumab on the frequency of VOC in patients with recurrent VOC. For time‐to‐first and time‐to‐second VOC, hazard ratios (HRs) were calculated for crizanlizumab vs placebo based on Cox regression analysis, with treatment as a covariate; data are presented as Kaplan‐Meier plots. n = 23bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. Search for other works by this author on: © 2016 by The American Society of Hematology, Copyright ©2020 by American Society of Hematology, https://doi.org/10.1182/blood.V128.22.1.1. The funder developed the statistical analysis plan, analyzed and had a role in interpreting the data, provided financial support for medical editorial assistance, and had a role in writing the report. SUSTAIN was a 52-week pivotal SCD study that evaluated clinically meaningful end points 1,2 Study description. The rates of treatment‐emergent adverse events were similar between treatment arms across all subgroups. Asterisk with author names denotes non-ASH members. David Gray (DG): Managing Editor of Advances in Therapy. The primary efficacy endpoint was the annual rate of SCPC in the 5.0 mg/kg SelG1 group vs. placebo. KIA has received fees for consultancy from Modus Therapeutics and Reprixys Pharmaceuticals Corporation, and has participated in advisory boards for Bioverativ, Global Blood Therapeutics and Novartis Pharmaceuticals Corporation. Demographic parameters were evenly distributed in the treatment groups. Raffaella Colombatt Data from SUSTAIN (NCT01895361) showed that in patients treated at the high 5 mg/kg dose, Adakveo significantly reduced the frequency of annual VOCsby a mean of 45.3% compared to those given placebo. Some patients in the trial were also receiving hydroxyurea. However, the greatest differences between the crizanlizumab and placebo arms were observed among patients not using concomitant HU (HR: 0.40; 95% CI 0.17‐0.93) and in the non‐HbSS genotype subgroup (HR: 0.30; 95% CI 0.11‐0.81) (Supporting Information Figure S1). In SUSTAIN, patients with SCD were randomized to crizanlizumab 2.5 mg/kg, crizanlizumab 5 mg/kg, or placebo intravenously 14 times over 52 weeks. Patients using concomitant HU were included if they had been receiving HU treatment for ≥6 months and at a stable dose for at least the previous 3 months; these patients were not allowed to have HU dose adjustments during the study, except for safety reasons (eg, dose interruption/reduction because a patient was not tolerating HU therapy). Sickle cell disease (SCD) is a genetic disorder that predominantly affects individuals of African descent.1 It is characterized by the presence of sickle hemoglobin (HbS), which polymerizes upon deoxygenation, damaging erythrocytes and potentially leading to vaso‐occlusion, multi‐organ damage, and early death.2 Painful vaso‐occlusive crises (VOCs), also known as sickle cell pain crises, are the hallmark of SCD and are the primary cause of hospitalization in SCD.3 VOCs cause pain in the extremities, back, abdomen or chest, and can vary in intensity from mild to excruciating.4 Patients with SCD and frequent VOCs may experience problems with low self‐esteem, anxiety, depression, dissatisfaction with body image, poor school performance, social isolation, decreased participation in normal daily activities, and poor peer and family relationships.4, The most common SCD genotype is homozygous hemoglobin S (HbSS) which, along with sickle β0‐thalassemia (HbSβ0), is generally considered to be the most clinically severe. No treatment‐related AEs led to death. n = 25bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. Despite the substantial burden of VOCs, there are currently few available treatment options and all have important limitations. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. and you may need to create a new Wiley Online Library account. The SUSTAIN trial involved 198 SCD patients ages 16–65 who had experienced at least two and as many as 10 pain crises during the previous year. Further analyses of secondary endpoints demonstrated that crizanlizumab treatment significantly increased time‐to‐first VOC vs placebo in these subgroups. This article reviews the evidence pertaining to crizanlizumab in SCD by searching records in Medline, Embase, and International Pharmaceutical Abstracts. In contrast, crizanlizumab targets intercellular adhesion including RBCs, platelets, neutrophils and endothelial cells. Within each subgroup, patients were evenly distributed between the crizanlizumab and placebo arms (see Supporting Information Table S1, for an expanded list of patient characteristics). In SUSTAIN, patients with SCD were randomized to crizanlizumab 2.5 mg/kg, crizanlizumab 5 mg/kg, or placebo intravenously 14 times over 52 weeks. A total of 6345 patients (97%) had continuous ECG recordings evaluable for analysis. There were no apparent increases in infections with SelG1 treatment. AK has received research funding from Novartis Pharmaceuticals Corporation and from Reprixys Pharmaceuticals Corporation (which was acquired by Novartis Pharmaceuticals Corporation on November 18, 2016), is a member of a data monitoring committee for BlueBird Bio, and Chair of a Data and Safety Monitoring Board for Sancilio & Co. JK has received research support from Reprixys Pharmaceuticals Corporation, has participated in advisory boards and other activities for Novartis Pharmaceuticals Corporation, has participated in advisory boards for BlueBird Bio and Prolong Pharmaceuticals, and has acted as a consultant for AstraZeneca. DKL, RDC, JRF and JMK‐M declared no conflicts of interest. Abdullah Kutlar, Sickle Cell Center, Medical College of Georgia, Augusta University, 989 Street Sebastian Way, EF 145C, Augusta, GA 30912. Novartis is committed to sharing with qualified external researchers, access to patient‐level data and supporting clinical documents from eligible studies. More patients were VOC event‐free in the crizanlizumab 5 mg/kg arm than in the placebo arm, including those with more frequent prior VOCs (ie, 5‐10; 28.0% vs 4.2%), the HbSS genotype (31.9% vs 17.0%) and/or using concomitant hydroxyurea (33.3% vs 17.5%). Learn more. Working off-campus? n = 39bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. ACS events were rare in this study. Develop, support, and sustain hemoglobinopathy clinical trial networks as well as a better infrastructure to better enroll and study people with SCD and share data, including in community settings (need collaboration for sufficient enrollment). OAA has participated in advisory boards for Novartis Pharmaceuticals Corporation. The randomization was stratified by historical SCPC in the prior year (2-4 or 5-10) and concomitant HU use (yes or no). If you do not receive an email within 10 minutes, your email address may not be registered, Although hydroxyurea (HU) is known to decrease the frequency of SCPC in sickle cell anemia, many patients continue to experience acute painful episodes despite such therapy. Although PSGL‐1 is not present on normal erythrocytes, sickled red blood cells (RBCs) are known to have glycoproteins on their cell surface that can mimic the P‐selectin ligand and mediate adherence to activated endothelial cells expressing P‐selectin.15, 16, Crizanlizumab is a humanized, anti‐P‐selectin monoclonal antibody.17 The 52‐week, phase 2 SUSTAIN study demonstrated that crizanlizumab has a potentially disease‐modifying effect when used for the prevention of VOCs in patients with SCD.17 In this study, crizanlizumab 5 mg/kg significantly reduced the frequency of VOCs by 45% (P = .01), significantly delayed the median time‐to‐first VOC by 2.7 months (P = .001) and second VOC by 5.2 months (P = .02), and appeared to decrease the annualized median rate of days hospitalized (for any cause) by 42% (4.00 vs 6.87 days) vs placebo in SCD patients aged ≥16 years, although the difference was not statistically significant due to large variability (P = .45) but may be considered clinically relevant.17. Further analysis of annualized days of hospitalization by subgroup was not feasible due to the sample size of the study, given that the overall analysis did not demonstrate statistically significant differences. The study enrolled 198 patients with SCD across 60 centers in the United States, Brazil, and Jamaica. All authors had access to analyzed data, contributed to the writing and reviewing of the report, and had final responsibility for the decision to submit for publication. HU is approved for patients who have had 3 or more VOCs in the previous year,18 and this post hoc analysis suggests that crizanlizumab can provide additional benefit compared with HU alone in patients who continue to experience VOCs despite HU treatment. Results showed that even among those who had experienced 5‐10 VOC events in the year prior to study entry, those using concomitant HU, and those with the more clinically severe HbSS genotype, crizanlizumab treatment increased the likelihood of being VOC event‐free compared with placebo. Patients were randomized to receive placebo, 2.5 mg/kg or 5.0 mg/kg SelG1; patients received their initial dose, a dose 14 days later, and then every 4 weeks through week 50 for a total of 14 doses. Chronic inhibition of P-selectin with once a month IV dosing of SelG1 represents a novel and potentially new disease-modifying, prophylactic treatment option for patients with SCD. Clinical trials are underway using different gene transfer vectors and cassettes. Five deaths occurred during the study, 2 at 5.0 mg/kg, 1 at 2.5 mg/kg and 2 in placebo; no deaths were deemed related to study drug. Patients were excluded if they were undergoing long‐term, RBC transfusion therapy. VOC event‐free patients were defined as those with zero annualized days with a VOC, regardless of whether patients completed the full duration of the study. Primary Purpose: Treatment. The results from this analysis will help to determine if the outcomes with crizanlizumab treatment were similar in all subgroups analyzed. Significant improvements were also achieved for several secondary endpoints including increases in times to first and second SCPC. As such, when we refer to the crizanlizumab group in this analysis we are referring to the 5 mg/kg dose. Adverse events that occurred in 5% or more of patients in an active dose group and were elevated over placebo by at least 2-fold were arthralgia, pruritus, vomiting, chest pain, diarrhea, road traffic accident, fatigue, myalgia, musculoskeletal chest pain, abdominal pain, influenza and oropharyngeal pain. Wally Smith, MD, Virginia Commonwealth University, Richmond, VA, outlines the findings of a post hoc analysis of length of opioid use in sickle cell disease (SCD) patients enrolled in the SUSTAIN trial (NCT01895361). Kanter:Novartis: Consultancy. Uncomplicated VOCs were defined as crises other than ACS, hepatic or splenic sequestration, or priapism. The procedures for the SUSTAIN study have been described in detail.17 In brief, patients received placebo or crizanlizumab at a dose of 2.5 or 5 mg/kg, administered intravenously 14 times over 52 weeks (2 loading doses in the first month followed by monthly infusions thereafter). About the Subgroup Analysis and the SUSTAIN trial The heterogeneity in severity of sickle cell disease and various other factors make it important to understand differences in response of various subgroups of patients in order to increase understanding of crizanlizumab and the role of P-selectin in SCD. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. o Data from the Hospital Episode Statistics (HES) database was used to estimate the risk of acute SCD-related complications or death associated with varying frequency of VOC. The methods for the SUSTAIN study have previously been described in detail.17 In brief, SUSTAIN was a phase 2, randomized, double‐blind, placebo‐controlled study consisting of a screening phase of 30 days, a treatment phase of 52 weeks, and a follow‐up evaluation phase of 6 weeks. Crizanlizumab, a P-selectin inhibitor, mitigates the microvascular vaso-occlusion in SCD. Safety assessments included frequency of treatment‐emergent adverse events (AEs) and treatment‐emergent serious adverse events (SAEs). Results: 198 SCD patients were randomized for the 1-year study. No hepatic or splenic sequestration events were reported among patients in either the crizanlizumab 5 mg/kg or placebo arms. One priapism event was reported in the placebo arm and none was reported in the crizanlizumab 5 mg/kg arm. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com. P-selectin is an adhesion molecule expressed on activated vascular endothelial cells and platelets. ZZ performed the analyses and contributed to the interpretation of the findings presented. About the SUSTAIN trial The Phase II SUSTAIN trial was a multicenter, multinational, randomized, placebo-controlled, double-blind,12-month study to assess safety and efficacy of the anti-P-selectin antibody crizanlizumab with or without concomitant use of hydroxyurea therapy in sickle cell disease patients with sickle cell-related pain crises. Crizanlizumab … Overall, these findings support the initial findings from the SUSTAIN study17 and suggest that crizanlizumab is a potentially disease‐modifying agent that reduces the frequency of, or prevents, VOCs in patients with SCD (of all genotypes). AB, MS and ZZ are employees of Novartis Pharmaceuticals Corporation. The purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit. Patients with SCD engrafted, had sustained production of the transgene and a decreased number of vaso-occlusive crises. n = 31bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. Descriptive statistics were used to summarize the number of VOC event‐free patients and types of VOC in the following subgroups: prior VOC events (2‐4 or 5‐10), genotype (HbSS or non‐HbSS), and concomitant HU use (yes or no). n = 11bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. All efficacy analyses were conducted using the intention‐to‐treat (ITT) population, which included all patients randomized to crizanlizumab 5 mg/kg or placebo. Rollins:Selexys Pharmaceuticals: Equity Ownership, Other: Previous Employment. n = 15bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. The observed reductions in VOCs suggest that P‐selectin inhibition can provide an additional treatment effect and, therefore, meets an existing unmet need based on the currently available treatment options. VOCs were defined as acute episodes of pain that were caused by a vaso‐occlusive event that resulted in a visit to a medical facility and treatment with oral or parenteral opioids or parenteral nonsteroidal anti‐inflammatory drugs. Key inclusion criteria included patients 16 to 65 years of age; diagnosis of SCD (HbSS, HbSC, HbSβ0 thalassemia or HbSβ+ thalassemia); and history of 2 to 10 SCPC in the previous 12 months. “In SUSTAIN, the 5.0 mg/kg dose was found … An SCPC was defined as acute sickle cell-related pain that resulted in a visit to a medical facility and required a parenteral or oral narcotic or parenteral NSAID. Most participants (91.9%) were Black or African American. Hydroxyurea in sickle cell disease: drug review, Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities, Adherence to hydroxyurea, health‐related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross‐sectional study in adolescents and young adults, A phase 3 trial of L‐glutamine in sickle cell disease, Allogeneic hematopoietic stem‐cell transplantation for sickle cell disease, The role of blood transfusion in sickle cell disease, Paucity of HLA‐identical unrelated donors for African‐Americans with hematologic malignancies: the need for new donor options, https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm418232.htm, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208587s000lbl.pdf, HU use/VOC events in the year prior to study. Over the course of the study, a greater proportion of patients in the crizanlizumab group (n = 24/67; 35.8%) did not experience a VOC, compared with patients in the placebo group (n = 11/65; 16.9%). The analysis focused on patient characteristics of interest, including those specified as stratification criteria in the original study protocol (number of VOC events in the year prior to study entry, and concomitant HU use) and genotype. Investigate combination therapies and new drug-delivery models. It should be noted that these data were generated through a post hoc analysis of a study that was not powered to detect differences between patient subgroups; caution is therefore advised when interpreting these data. Patients were randomized by an interactive voice or web response system to receive crizanlizumab 2.5 mg/kg, crizanlizumab 5 mg/kg, or placebo. Primary results were published in The New … 1) and time to second SCPC was increased 2.0-fold (medians of 10.3 vs. 5.1 months, p = 0.022, Fig. Methods: We conducted a randomized, double-blind, placebo-controlled, multinational study. Patients included in the trial were 16 to 65 years of age, had sickle cell disease (SCD) of any genotype (HbSS, HbSC, HbS/beta . 33 The SUSTAIN trial, a multicenter randomized double blind study, showed that crizanlizumab decreased the incidence of VOC by 45% in patients with or without HU. SUSTAIN clinical trial data. SUCCESSOR is a retrospective cohort study of adult patients (≥18 years old) who participated in the SUSTAIN study in the United States to evaluate outcomes related to SCD up to 52 weeks following their completion of the trial. No evaluation of crizanlizumab 2.5 mg/kg was included in this analysis because the primary endpoint of the study was only met with the 5 mg/kg dose and therefore this is the dose for which further clinical development is planned. The most marked increases observed were in the HbSS genotype subgroup (4.07 months in the crizanlizumab group vs 1.12 months in the placebo group; HR: 0.50; 95% CI 0.31‐0.80) and no concomitant HU use (5.68 vs 2.86 months; HR: 0.39; 95% CI 0.20‐0.76) (Table 2; Figure 2). CLIMB-SCD-121: An ongoing Phase 1/2 open-label trial, designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 18 to 35 with severe SCD. The primary endpoint was the annual rate of VOC with crizanlizumab vs placebo. Blood 2016; 128 (22): 1. doi: https://doi.org/10.1182/blood.V128.22.1.1. Study Start Date : The primary endpoint, the annual rate of SCPC in the ITT population at 5.0 mg/kg vs. placebo, was reduced 47% (medians of 1.6 vs. 3.0, p = 0.010, Table 1). The annual rate of uncomplicated SCPC at 5.0 mg/kg vs. placebo was reduced by 62% (medians of 1.1 vs. 2.9, p = 0.015). In the Phase II SUSTAIN study, crizanlizumab 5.0 mg/kg significantly reduced the median annual rate of VOCs compared with placebo (P=0.010). The FDA’s approval decision was based on data from the randomized, double-blind, and placebo-controlled Phase 2 SUSTAIN (NCT01895361) trial in 198 SCD patients with a history of frequent VOCs (two to 10 episodes the year prior to enrolling in the study). Patients were randomly assigned to receive 5 mg/kg or 2.5 mg/kg of SelG1 or a placebo intravenously once a month, after an initial loading dose. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Results from the Phase 2 SUSTAIN clinical trial demonstrated that crizanlizumab (SEG101, Selexys Pharmaceuticals, Novartis), an anti-P-selectin antibody, reduced by 45.3% the median annual rate of sickle cell-related pain crises (SCPC), compared to placebo in patients with or without hydroxyurea therapy, a drug used to reduce the rate of painful attacks in sickle-cell disease (SCD). In the SUSTAIN study, 198 patients met the eligibility criteria, of whom 67 were assigned to receive crizanlizumab 5 mg/kg and 65 to receive placebo (giving a total of 132 patients in the subgroup analyses) (Figure 1). Crizanlizumab, a P‐selectin inhibitor, mitigates the microvascular vaso‐occlusion in SCD. Kenneth I. Ataga, Abdullah Kutlar, Julie Kanter, Darla Liles, Rodolfo Cancado, João Friedrisch, Troy H. Guthrie, Jennifer Knight-Madden, Ofelia A. Alvarez, Victor R. Gordeuk, Sandra Gualandro, Marina Pereira Collela, Wally R. Smith, Scott A. Rollins, Jonathan W. Stocker, Russell P. Rother; SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. The frequency of treatment‐emergent AEs and SAEs for crizanlizumab 5 mg/kg and placebo was generally consistent across all the subgroups analyzed. Learn about our remote access options, Sickle Cell Center, Medical College of Georgia, Augusta University, Augusta, Georgia. Crizanlizumab also consistently delayed time‐to‐first and time‐to‐second VOC compared with placebo in all subgroups. clinicaltrials.gov: NCT01895361. Gene therapies are being developed, and several are now in various stages of early-phase human clinical trials. In SUSTAIN, patients with SCD were randomized to crizanlizumab 2.5 mg/kg, crizanlizumab 5 mg/kg, or placebo intravenously 14 times over 52 weeks. Conclusions: The P-selectin inhibitor SelG1 significantly reduced SCPC and appeared to be safe and well tolerated. The drug was approved in the USA26 based on results from a phase 3 study that have recently been published.27 At the time of writing, no additional real‐world experiences are available for this new treatment option. The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Each patient will be asked to participate in a long-term follow-up study. n = 21bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. It is a key molecule in the initiation of leukocyte rolling on the vessel wall that leads to firm attachment and extravasation to underlying tissues during inflammation. The funder had no role in the design or conduct of the SUSTAIN study or in data collection. n = 28bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. double-blind, multicenter, phase 2 study of 198 patients with sickle cell disease (SUSTAIN trial; NCT01895361) . Giovanna Russo (GR): Department of Clinical and Experimental Medicine, University of Catania, Catania. Patients receiving HU or erythropoietin were included if prescribed for the preceding 6 months and dose was stable for at least 3 months. The median rate of uncomplicated VOCs was lower for crizanlizumab 5 mg/kg than placebo across all subgroups (Supporting Information Table S2). Non‐drug therapeutic options for patients with SCD include stem cell transplant28 and blood transfusions.29 Stem cell transplant is not a viable option for many patients owing to the lack of suitable donors,30 and although blood transfusions can play a vital role in treating the acute and chronic complications of SCD, they can also cause alloimmunization, hyperhemolytic transfusion reactions, and iron overload.29. Sickle cellrelated pain crises are the primary cause of health care encounters in patients with sickle cell disease.1 These crises result in a decrease in quality of life2 and an increase in the risk of death.3 Crises … The annual rate of days hospitalized at 5.0 mg/kg vs. placebo showed a non-significant, 42% reduction (medians of 4.0 vs. 6.9, p = 0.450). Of these patients, more had experienced 2‐4 VOCs (n = 83/132, 62.9%) than 5‐10 VOCs in the year prior to study (n = 49/132, 37.1%). The Intent-To-Treat (ITT) population included all randomized patients; 67, 66 and 65 patients in the 5.0 mg/kg, 2.5 mg/kg and placebo groups, respectively. n = 32bb Number of patients included in the subgroup who experienced any VOC during the SUSTAIN study. Kutlar:Novartis Pharmaceuticals: Research Funding. The median rate of ACS was 0 in each treatment arm, with a total of 18 ACS events in 14 patients treated with crizanlizumab 5 mg/kg and 15 ACS events in 13 patients treated with placebo. The SUSTAIN study evaluated the safety of SelG1, a first-in-class humanized anti-P-selectin antibody, and its effect on the frequency of SCPC in SCD patients. Descriptive statistics were used to summarize patient demographics and baseline characteristics in the ITT population, and frequency of AEs and SAEs in the safety population, which included all randomized patients who received at least 1 dose of either crizanlizumab 5 mg/kg or placebo. Both the U.S. approval and the new CHMP opinion were based on the results of the SUSTAIN Phase 2 clinical trial (NCT01895361). … A subgroup analysis of the primary endpoint (annual rate of VOCs) highlighted that a lower frequency of crises was observed with crizanlizumab 5 mg/kg vs placebo regardless of the number of prior VOC events, concomitant hydroxyurea (HU) use or SCD genotype.17 We therefore conducted a post hoc analysis to further evaluate different endpoints in these same subgroups, including the proportion of patients who did not experience a VOC during the study, additional secondary efficacy endpoints and the safety of crizanlizumab 5 mg/kg compared with placebo. Antiplatelet agents. Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username, Time‐to‐first on‐treatment VOC by prior VOC events, SCD genotype, and HU use Abbreviations: HbSS, hemoglobin S; HU, hydroxyurea; SCD, sickle cell disease; VOC, vaso‐occlusive crisis, I have read and accept the Wiley Online Library Terms and Conditions of Use, The pain experience of patients with sickle cell anemia, Essential of sickle cell disease management, Recent Advances in Pediatric Medicine; Synopsis of Current General Pediatrics Practice, Minireview: genetic basis of heterogeneity and severity in sickle cell disease, The effect of deoxygenation on whole‐cell conductance of red blood cells from healthy individuals and patients with sickle cell disease, Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology, Vaso‐occlusion in sickle cell disease: pathophysiology and novel targeted therapies, Platelet activation and platelet‐erythrocyte aggregates in patients with sickle cell anemia, Platelet‐neutrophil‐interactions: linking hemostasis and inflammation, Inhibition of cell adhesion by anti‐P‐selectin aptamer: a new potential therapeutic agent for sickle cell disease, P‐selectin mediates the adhesion of sickle erythrocytes to the endothelium, Heparin inhibits the flow adhesion of sickle red blood cells to P‐selectin, Crizanlizumab for the prevention of pain crises in sickle cell disease, Hydroxyurea for the treatment of sickle cell anemia, How I use hydroxyurea to treat young patients with sickle cell anemia, The FDA encourages new treatments for sickle cell disease, Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia.
Busreise Saarbrücken Prag, Zahnhälse Versiegeln Sinnvoll, Ikea Barnslig Nilpferd Neu, Silvester Essen Tradition österreich, Soufian Net Worth, Ikea Barnslig Nilpferd Neu, Starke Blutung Am Hodensack, Pubertät Bei Asperger Autisten, Biber Bettwäsche 135x200 4-tlg Grau,